Medication info

Metoglin Tablets 2.5/1000 Milligrams

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
You & Life Science Co., Ltd.
Appearance
Light pink, biconvex, oval film-coated tablet
Packaging
60 tablets (10 tablets/PTP packaging x 6 packs)
Approval status
Expired

MFDS item code 201907072 · Approved 2019.10.04

This product's status changed to Expired on 2024.10.04. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined in consideration of each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, increase the dose gradually. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients with inadequate blood glucose control on metformin monotherapy: The initial dose of this medicine is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's existing metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from linagliptin and metformin combination therapy: Patients switching from linagliptin and metformin combination therapy to this medicine should start with their existing doses of linagliptin and metformin. 4. Patients with inadequate blood glucose control on metformin and sulfonylurea combination therapy: The initial dose should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia. 5. Patients with inadequate blood glucose control on insulin and metformin combination therapy: The initial dose should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
You & Life Science Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood sugar control
View approved original text

This medication is used to assist in blood sugar control in adults with type 2 diabetes in conjunction with diet and exercise therapy. It may be administered when there is no prior experience with diabetes medication or when blood sugar control is difficult with monotherapy. Additionally, it can be used alternately or in combination when sufficient blood sugar control cannot be achieved with monotherapy of metformin or combination therapy of linagliptin and metformin. It can also be administered to improve blood sugar control in cases where blood sugar control is inadequate despite maximum doses of metformin and sulfonylureas, insulin, or empagliflozin. This medication effectively aids in blood sugar management across multiple treatment stages.

How to take

Adult dose

The dose of this medicine should be determined in consideration of each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, increase the dose gradually. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients with inadequate blood glucose control on metformin monotherapy: The initial dose of this medicine is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's existing metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from linagliptin and metformin combination therapy: Patients switching from linagliptin and metformin combination therapy to this medicine should start with their existing doses of linagliptin and metformin. 4. Patients with inadequate blood glucose control on metformin and sulfonylurea combination therapy: The initial dose should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia. 5. Patients with inadequate blood glucose control on insulin and metformin combination therapy: The initial dose should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication has the potential to cause a serious side effect known as lactic acidosis, so caution is necessary. It should not be used in patients with allergies to its active ingredients or in those with type 1 diabetes, lactic acidosis, or diabetic ketoacidosis. Patients with severely impaired kidney function or in conditions that may cause acute kidney injury should not take this medication. Patients with severely impaired heart or lung function, liver dysfunction, acute alcohol intoxication, or alcoholism should also avoid this medication. Pregnant or breastfeeding women should refrain from using this medication, and those planning a pregnancy should consult a specialist. Caution is advised when using this medication with other blood glucose-lowering agents as there may be a risk of hypoglycemia, especially when combined with sulfonylureas or insulin, which may require dosage adjustments. To reduce the risk of lactic acidosis, kidney function should be regularly monitored, and if symptoms of dehydration, severe infection, or heart failure occur, the use of this medication should be immediately discontinued. It is advisable to temporarily discontinue this medication prior to and after surgery or radiographic iodine contrast examinations. This medication may lower vitamin B12 levels, so it is recommended to regularly check for vitamin B12 deficiency during prolonged use. It may interact with other medications, so patients should inform their doctor or pharmacist of any other medications they are taking. Elderly patients may be at higher risk for decreased kidney function, thus careful dose adjustment and frequent monitoring of kidney function is necessary. Acute pancreatitis or bullous pemphigoid, a skin disease, may occur during treatment; patients should consult medical personnel immediately if abdominal pain or skin abnormalities develop. In case of overdose, there is an increased risk of lactic acidosis, so immediate medical attention is required if symptoms appear. This medication is not recommended for children or pediatric patients under the age of 10. It should be stored out of reach of children, kept away from moisture, and not transferred to other containers.

Side effects

Lactic acidosis, nasopharyngitis, hypersensitivity, angioedema, urticaria, vitamin B12 decrease and deficiency, hypoglycemia, taste disturbance, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular pemphigoid, arthralgia with severe and disabling symptoms, rhabdomyolysis, increased lipase, increased amylase, constipation, epigastric pain, enterocolitis, bowel obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disturbance, Alzheimer's dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, metastasis to the liver, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, hearing loss, dizziness, erectile dysfunction, goiter, kidney transplant failure, anemia, headache, sensory disturbance, post-herpetic neuralgia, hemiparesis, syncope, drowsiness, chest discomfort, myasthenia, epistaxis, oropharyngeal pain, voice disorder, nasal bleeding, male pattern baldness, hyperhidrosis, hair loss, dermatitis, anxiety, insomnia, depression, hypertension, benign prostatic hyperplasia, angina pectoris, acute myocardial infarction, unstable angina, diarrhea, pancreatitis, stomatitis, mediastinitis, pneumonia, rhinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, anal bleeding, cheilitis, dental caries, enteritis, gastritis, stomatitis, dizziness, diabetic neuropathy, subdural effusion, delusional state, nocturia, pruritus, hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture and should be stored in a tightly closed container. Additionally, it is best to avoid excessively hot or cold locations, storing it at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Light pink, biconvex, oval film-coated tablet

Package unit

60 tablets (10 tablets/PTP packaging x 6 packs)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.